Tryptamine Therapeutics (AU:TYP) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Tryptamine Therapeutics Limited has announced a change in the indirect interests of its director Chris Ntoumenopoulos. The company disclosed the acquisition of director options, including 3.5 million options at $0.03, 3.5 million options at $0.04, and 8.75 million options at $0.05, all set to vest and expire between 2024 and 2030.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.